BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 21460603)

  • 1. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis.
    Gupta T; Kannan S; Dantkale V; Laskar S
    Hematol Oncol Stem Cell Ther; 2011; 4(1):17-29. PubMed ID: 21460603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.
    Lei XR; Chen HL; Wang FX; Bai J; He AL
    Int J Clin Exp Med; 2015; 8(8):12064-75. PubMed ID: 26550118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission.
    Litzow MR; Pérez WS; Klein JP; Bolwell BJ; Camitta B; Copelan EA; Gale RP; Giralt SA; Keating A; Lazarus HM; Marks DI; McCarthy PL; Miller CB; Milone G; Prentice HG; Russell JA; Schultz KR; Trigg ME; Weisdorf DJ; Horowitz MM
    Br J Haematol; 2002 Dec; 119(4):1115-24. PubMed ID: 12472596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
    Zhang H; Fan Z; Huang F; Han L; Xu Y; Xu N; Deng L; Wang S; Lin D; Luo X; Zhang Q; Liu X; Li X; Liang X; Xie S; Qu H; Yu S; Zhou H; Shi P; Xuan L; Lin R; Liu H; Jin H; Sun J; Liu Q
    J Clin Oncol; 2023 Jan; 41(2):343-353. PubMed ID: 36084276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of cladribine in combination with busulfan and cyclophosphamide as an intensive conditioning regimen preceding allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Xiao F; Guo H; Yan X; Qi M; Zhang J
    Transpl Immunol; 2024 Jun; 84():102037. PubMed ID: 38499049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis.
    Shi-Xia X; Xian-Hua T; Hai-Qin X; Bo F; Xiang-Feng T
    Leuk Lymphoma; 2010 Jan; 51(1):50-60. PubMed ID: 20055658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study.
    Sakellari I; Gavriilaki E; Chatziioannou K; Papathanasiou M; Mallouri D; Batsis I; Bousiou Z; Bouziana S; Constantinou V; Douka V; Apostolou C; Iskas M; Lalayanni C; Athanasiadou A; Sotiropoulos D; Yannaki E; Gianouzakos V; Anagnostopoulos A
    Ann Hematol; 2018 Oct; 97(10):1987-1994. PubMed ID: 29869673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
    Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
    J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
    Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
    Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
    J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
    Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    Ling Y; Xuan L; Xu N; Huang F; Fan Z; Guo Z; Xu X; Liu H; Lin R; Yu S; Zhang H; Jin H; Wu M; Liu C; Liang X; Ou R; Zhang Y; Liu X; Qu H; Zhai X; Sun J; Zhao Y; Liu Q
    J Clin Oncol; 2023 Oct; 41(29):4632-4642. PubMed ID: 37335960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant.
    Eroglu C; Pala C; Kaynar L; Yaray K; Aksozen MT; Bankir M; Zararsız G; Orhan O; Gündog M; Yıldız OG; Eser B; Cetin M; Unal A
    Leuk Lymphoma; 2013 Nov; 54(11):2474-9. PubMed ID: 23442062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.
    Nagler A; Savani BN; Labopin M; Polge E; Passweg J; Finke J; Kyrcz-Krzemien S; Volin L; Anagnostopoulos A; Aljurf M; Beelen DW; Vigouroux S; Milpied N; Suarez F; Mohty M
    Lancet Haematol; 2015 Sep; 2(9):e384-92. PubMed ID: 26685771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
    J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulfan-containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study.
    Wang YH; Tien FM; Tsai CH; Huang HH; Liu JH; Liao XW; Tang JL; Yao M; Ko BS
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1488. PubMed ID: 34196132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia.
    Uberti JP; Agovi MA; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringdén O; Weisdorf DJ; Rizzo JD
    Bone Marrow Transplant; 2011 Jan; 46(1):34-43. PubMed ID: 20400989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.